Takeshi Nagashima
Overview
Explore the profile of Takeshi Nagashima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
3830
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashizawa T, Iizuka A, Kanematsu A, Ando T, Maeda C, Miyata H, et al.
In Vivo
. 2024 Dec;
39(1):80-95.
PMID: 39740910
Background/aim: Immune checkpoint blockade has achieved great success as a targeted immunotherapy for solid cancers. However, small molecules that inhibit programmed death 1/programmed death ligand 1 (PD-1/PD-L1) binding are still...
2.
Kakuda Y, Kato I, Kawata T, Goto K, Ito K, Satake R, et al.
Pathol Int
. 2024 Dec;
75(1):40-45.
PMID: 39641230
NTRK-rearranged spindle cell neoplasm is a group of tumors characterized by NTRK1/2/3 gene fusion. Recently, tumors with other kinase fusion genes were reported to exhibit similar morphologies. Herein, we discuss...
3.
Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells
Chen Y, Takada M, Nagornyuk A, Muhan W, Yamada H, Nagashima T, et al.
bioRxiv
. 2024 Nov;
PMID: 39574707
Microtubule-targeting agents (MTAs) have been successfully translated from basic research into clinical therapies and have been widely used as first- and second-line chemotherapy drugs for various cancers. However, current MTAs...
4.
Fujiya K, Serizawa M, Ohshima K, Umehara R, Watanabe Y, Nagashima T, et al.
Anticancer Res
. 2024 Oct;
44(11):4779-4788.
PMID: 39477296
Background/aim: Biomarkers indicating sensitivity to poly ADP-ribose polymerase (PARP) inhibitors have not yet been identified in gastric cancer. PARP inhibitors target homologous recombination deficiency (HRD); however, homologous recombination (HR) induces...
5.
Okada S, Serizawa M, Sato F, Goto S, Nagashima T, Ohshima K, et al.
Int Cancer Conf J
. 2024 Oct;
13(4):412-421.
PMID: 39398935
Biphenotypic sinonasal sarcoma (BSNS) is a double-phenotype sarcoma that shows differentiation in both the nervous and muscular systems. To date, whole-genome and transcriptome sequencing (WGTS) has not been used to...
6.
Nagashima T, Yamaguchi K, Urakami K, Shimoda Y, Ohnami S, Ohshima K, et al.
Sci Rep
. 2024 Oct;
14(1):23898.
PMID: 39396060
In cancer genome analysis, identifying pathogenic alterations and assessing their effects on oncogenic processes is important. Although whole exome sequencing (WES) can effectively detect such changes, driver alterations could not...
7.
Kasai S, Kagawa H, Hatakeyama K, Shiomi A, Manabe S, Yamaoka Y, et al.
Int J Clin Oncol
. 2024 Sep;
29(12):1887-1895.
PMID: 39287842
Background: The association between the molecular profiles and prognosis of Stage II colorectal cancer remains unclear. This study aimed to examine the risk factors for relapse of Stage II colorectal...
8.
Inoue M, Tsubosa Y, Ohnami S, Tokizawa K, Mayanagi S, Ohshima K, et al.
Surg Case Rep
. 2024 Aug;
10(1):191.
PMID: 39158654
Background: Esophageal carcinosarcoma (ECS) is a relatively rare malignancy, accounting for < 1% of all esophageal cancers. Its etiopathogenesis remains unknown. This study analyzed the genomic abnormalities in sarcomatous tumors...
9.
Chen K, Okamura Y, Hatakeyama K, Shiomi A, Kagawa H, Hino H, et al.
Surg Today
. 2024 Jul;
55(2):273-282.
PMID: 39083120
Purpose: Unresectable recurrence is a critical predictor of outcomes for colorectal cancer patients. We attempted to identify the prognostic factors, especially for unresectable recurrence-free survival (URFS) as a new endpoint,...
10.
Yamada H, Takada M, Ghone D, Yu M, Nagashima T, Fujimoto H, et al.
Sci Rep
. 2024 Jun;
14(1):14146.
PMID: 38898119
Eribulin (ERI), clinically utilized for locally advanced or metastatic breast tumors, has shown potential links to the immune system. Notably, the cGAS-STING pathway, a key component of innate immunity, has...